Medincell Stock: price and insider trades · France

The first major product developed from this platform is UZEDY®, a risperidone-based antipsychotic approved by the U.S. FDA in 2023 for the treatment of schizophrenia in adults and commercialized in the United States by Teva. UZEDY is strategically important because it demonstrates Medincell’s ability to turn formulation innovation into an industrial product with global commercial relevance. In 2025, the company also announced approvals for this risperidone LAI in Canada and South Korea under the LONGAVO® brand, while Teva reported strong growth in UZEDY net sales in 2025. In parallel, the olanzapine LAI program reached another milestone when the FDA accepted the NDA in February 2026, underscoring the depth of the pipeline.

Medincell operates a licensing-driven business model built on partnerships with major pharmaceutical companies. This structure generates royalties on worldwide sales and milestone payments while reducing the capital intensity of maintaining a large commercial organization. The company has an international footprint through its partnerships, especially with Teva, and actively participates in investor conferences in the United States and Europe. Its positioning as a “clinical- and commercial-stage biopharmaceutical licensing company” makes it a distinctive player in the French market, combining pharmaceutical innovation, technology transfer, and intellectual property monetization.